All in-house stories

Reset all filters
Channels & Sectors
Geography
Company
Refine search
California votes for law to restrict use of genAI by lawyers
Regulation & Industry
Lawmakers support a bill that would place guardrails on lawyers’ use of generative AI for court filings, in a bid to clamp down on AI ‘hallucinations’ and inaccuracies.   4 September 2026
FDA targets faster generic approvals in drive to slash drug prices
Regulation & Industry
Dozens of new and revised guidances could make it faster and less costly to bring generics to market, as the US ramps up pressure on drug prices.   27 August 2026
China-origin biotech assets and the hidden question of IP ownership
Biotech
As China-origin biotech assets flood the market, licensing deals are booming. Yet, the real strategic battle isn't just about the science—it’s about who controls the underlying IP, says Paul Calvo of Sterne Kessler   27 August 2026
Regulation & Industry
While promising science draws in buyers, intellectual property determines the price, terms, and viability of an agreement. LSIPR digs into what investors are looking for—and the biggest turn-offs that destroy a deal.   25 August 2026
Regulation & Industry
Labour MP for Stockton North takes up a new role as Minister for Science, Innovation and Investment within Andy Burnham’s government.   24 August 2026
MedTech
A new UPC Court of Appeal ruling closes an important procedural gap, with significant implications for how in-house teams structure validity defences, manage litigation costs and prepare for appeals, says Florian Laus of Simmons & Simmons.   7 August 2026
In-house counsel
A transatlantic firm with intellectual property at its heart—what’s not to like? The firm’s 30-year veteran tells WIPR why leading a recruitment drive is a “big responsibility” as the combined firm looks to out-scale the opposition.   4 August 2026
Regulation & Industry
Dealmaking is at a record pace, but not every asset is in play. So what are the therapy areas commanding the fiercest bidding wars and what’s to come?   29 July 2026
Regulation & Industry
With billions in revenue set to disappear as patents expire, pharmaceutical giants are racing to acquire their way out of trouble. But are there other drivers behind the surge—and how long can the momentum last?   27 July 2026
In-house counsel
As Philips' Kevin Scott becomes the IP Federation’s new president, Sarah Speight discovers the key issues facing the membership body for in-house counsel.   24 July 2026